beta-IsosparteineCAS# 24915-04-6 |
- (+)-Sparteine
Catalog No.:BCC9249
CAS No.:492-08-0
- (-)-Sparteine
Catalog No.:BCN9914
CAS No.:90-39-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 24915-04-6 | SDF | Download SDF |
PubChem ID | 168213 | Appearance | Powder |
Formula | C15H26N2 | M.Wt | 234.38 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
SMILES | C1CCN2CC3CC(C2C1)CN4C3CCCC4 | ||
Standard InChIKey | SLRCCWJSBJZJBV-AJNGGQMLSA-N | ||
Standard InChI | InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Sparteine is a class 1a antiarrhythmic agent, a sodium channel blocker. The deficient debrisoquine hydroxylation of Sparteine is due to the absence of P-450IID1 protein in the livers of poor metabolizers. |
Targets | P450 (e.g. CYP17) |
In vitro | Highly enantioselective (-)-sparteine-mediated lateral metalation-functionalization of remote silyl protected ortho-ethyl N,N-dialkyl aryl O-carbamates.[Pubmed: 25521308 ]J Org Chem. 2015 Apr 3;80(7):3368-86.
|
Structure Identification | J Am Chem Soc. 2010 Oct 6;132(39):13922-7.Synthesis of P-stereogenic compounds via kinetic deprotonation and dynamic thermodynamic resolution of phosphine sulfides: opposite sense of induction using (-)-sparteine.[Pubmed: 20843035]
A systematic study of the asymmetric deprotonation of a dimethyl-substituted phosphine sulfide using organolithium bases in the presence of (-)-Sparteine has been carried out.
Org Biomol Chem. 2014 Dec 14;12(46):9357-65.Revisiting the sparteine surrogate: development of a resolution route to the (-)-sparteine surrogate.[Pubmed: 25297971]The improved performance of the sparteine surrogate compared to sparteine in a range of applications has highlighted the need to develop an approach to the (-)-Sparteine surrogate, previously inaccessible in gram-quantities.
|
beta-Isosparteine Dilution Calculator
beta-Isosparteine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 4.2666 mL | 21.3329 mL | 42.6658 mL | 85.3315 mL | 106.6644 mL |
5 mM | 0.8533 mL | 4.2666 mL | 8.5332 mL | 17.0663 mL | 21.3329 mL |
10 mM | 0.4267 mL | 2.1333 mL | 4.2666 mL | 8.5332 mL | 10.6664 mL |
50 mM | 0.0853 mL | 0.4267 mL | 0.8533 mL | 1.7066 mL | 2.1333 mL |
100 mM | 0.0427 mL | 0.2133 mL | 0.4267 mL | 0.8533 mL | 1.0666 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- H-Ala-OMe.HCl
Catalog No.:BCC3192
CAS No.:2491-20-5
- H-Met-OMe. HCl
Catalog No.:BCC2995
CAS No.:2491-18-1
- Bakkenolide III
Catalog No.:BCN7245
CAS No.:24909-95-3
- Mesembrine
Catalog No.:BCN3668
CAS No.:24880-43-1
- Boc-Met-OH
Catalog No.:BCC3424
CAS No.:2488-15-5
- Erlotinib mesylate
Catalog No.:BCC1558
CAS No.:248594-19-6
- Azaphen
Catalog No.:BCC1390
CAS No.:24853-80-3
- Boc-Lys(Boc)-OH
Catalog No.:BCC3412
CAS No.:2483-46-7
- Laquinimod (ABR-215062)
Catalog No.:BCC3802
CAS No.:248281-84-7
- Agmatine sulfate
Catalog No.:BCC6813
CAS No.:2482-00-0
- Reserpinine
Catalog No.:BCN3490
CAS No.:24815-24-5
- H-Cys(tBu)-OH.HCl
Catalog No.:BCC2910
CAS No.:2481-09-6
- Sarracine
Catalog No.:BCN2021
CAS No.:2492-09-3
- Ethyl 3-cyclopropyl-3-oxopropanoate
Catalog No.:BCC8974
CAS No.:24922-02-9
- Varenicline
Catalog No.:BCC4155
CAS No.:249296-44-4
- Poly(I:C)
Catalog No.:BCC6138
CAS No.:24939-03-5
- Scutebarbatine N
Catalog No.:BCN8385
CAS No.:960302-87-8
- Demethoxy-3-epifumitremorgin C
Catalog No.:BCC8315
CAS No.:106292-68-6
- NFAT Inhibitor
Catalog No.:BCC2463
CAS No.:249537-73-3
- 2beta-Hydroxygrandiflorenic acid
Catalog No.:BCN8447
CAS No.:24967-93-9
- 1,2-Benzanthraquinone
Catalog No.:BCC8410
CAS No.:2498-66-0
-
SB-334867 hydrochloride
Catalog No.:BCC4289
CAS No.:249889-64-3
- Borreriagenin
Catalog No.:BCN5115
CAS No.:249916-07-2
- Anamorelin
Catalog No.:BCC1362
CAS No.:249921-19-5
Highly enantioselective (-)-sparteine-mediated lateral metalation-functionalization of remote silyl protected ortho-ethyl N,N-dialkyl aryl O-carbamates.[Pubmed:25521308]
J Org Chem. 2015 Apr 3;80(7):3368-86.
We report the enantioselective, lateral deprotonation of ortho-protected or functionalized tertiary N,N-dialkyl aryl O-carbamates 5-7 (Scheme 2 ) and meta-protected carbamates 14, 15, and 20 (Schemes 5 and 7 ) by s-BuLi/(-)-sparteine and subsequent quench with a variety of electrophiles to give products 11-13 and 16, 17, and 21 in yields up to 96% and enantiomeric ratios up to 99:1. The influence of organolithium reagents, ratio of organolithium/(-)-sparteine pair versus N,N-dialkyl aryl O-carbamate starting materials, temperature, solvents, electrophiles, substituents located ortho or meta to the O-carbamate moiety, and O-carbamate N-substituents was investigated. The identical absolute configuration of the stereogenic center of the major enantiomers of the products, as established by single-crystal X-ray analysis for substrates (S)-11c, (S)-19, and (S)-21a, provides evidence for a consistent stereochemical course in the enantioselective deprotonation. Mechanistic investigations, including an estimate of the configurational stability of the benzyllithium species 9 (starting from 12e; Scheme 8 ) and 23 (starting from 17e; Scheme 9 ), both derived by tin-lithium exchange, and 24 (starting from 20; Scheme 9 ) are reported. The experimental results, together with semiempirical molecular orbital calculations (PM3/SMD), are consistent with a process in which enantioinduction occurs in the deprotonation step (Scheme 11 ).
Revisiting the sparteine surrogate: development of a resolution route to the (-)-sparteine surrogate.[Pubmed:25297971]
Org Biomol Chem. 2014 Dec 14;12(46):9357-65.
The improved performance of the sparteine surrogate compared to sparteine in a range of applications has highlighted the need to develop an approach to the (-)-sparteine surrogate, previously inaccessible in gram-quantities. A multi-gram scale, chromatography-free synthesis of the racemic sparteine surrogate and its resolution via diastereomeric salt formation with (-)-O,O'-di-p-toluoyl-l-tartaric acid is reported. Resolution on a 10.0 mmol scale gave the diastereomeric salts in 33% yield from which (-)-sparteine surrogate of 93 : 7 er was generated. This work solves a key limitation: either enantiomer of the sparteine surrogate can now be readily accessed.
Synthesis of P-stereogenic compounds via kinetic deprotonation and dynamic thermodynamic resolution of phosphine sulfides: opposite sense of induction using (-)-sparteine.[Pubmed:20843035]
J Am Chem Soc. 2010 Oct 6;132(39):13922-7.
A systematic study of the asymmetric deprotonation of a dimethyl-substituted phosphine sulfide using organolithium bases in the presence of (-)-sparteine has been carried out. Use of nBuLi and (-)-sparteine in Et(2)O at -78 degrees C gave trapped adducts in approximately 88:12 er via a kinetically controlled process that was successfully predicted using a computational approach at the B3LYP/6-31+G(d) level. This initial kinetic enantioselectivity could be enhanced up to 97:3 er by trapping the lithiated intermediate with a prochiral electrophile (e.g., pivaldehyde or tBuPCl(2)). In addition, it was found that the R(P) and S(P) stereoisomers of the lithiated methylphosphine sulfide could interconvert at temperatures above 0 degrees C. Such interconversion is unprecedented and differs from the configurational instability of organolithiums that are stereogenic at a lithiated carbon atom. The major, thermodynamically preferred diastereomeric (-)-sparteine-complexed lithated phosphine sulfide was investigated by X-ray crystallography and computational methods at the B3LYP/6-31+G(d) level. Through the interconversion of the R(P) and S(P) stereoisomers of the lithiated methylphosphine sulfide, a novel dynamic thermodynamic resolution of a racemic lithiated phosphine sulfide has been developed. Thus, the phosphine sulfide was lithiated with nBuLi, and then (-)-sparteine was added. After equilibration at 0 degrees C for 3 h, electrophilic trapping generated an adduct in 81:19 er with the configuration opposite to that obtained under kinetic control. Thus, the methodology provides access to P-stereogenic compounds with the opposite sense of induction using (-)-sparteine as the ligand simply by changing the reaction conditions (kinetic or thermodynamic control).